BFM
EVOK

Boothbay Fund Management’s Evoke Pharma EVOK Stock Holding History

Boothbay Fund Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-107
Closed -$23K – 780
2019
Q1 		$23K Sell
107
-254
-70% -$86.6K ﹤0.01% 723
2018
Q4 		$129K Buy
361
+81
+29% +$30K 0.02% 529
2018
Q3 		$120K Buy
+280
New +$112K 0.01% 703

Other funds holding EVOK

SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Boothbay Fund Management's EVOK Position: Q2 2019 in Review

Boothbay Fund Management sold out of Evoke Pharma (EVOK) in Q2 2019, closing a stake of 107 shares — an estimated $23K sold.

Boothbay Fund Management first reported a position in EVOK in Q3 2018 and held it in 3 quarters. The position peaked at $129K in Q4 2018. 19 funds tracked by Wall St. Rank hold EVOK as of Q2 2019.

  • Boothbay Fund Management reported no remaining Evoke Pharma position as of Q2 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 107 Evoke Pharma shares in Q2 2019, an estimated $23K.
  • Boothbay Fund Management first reported a position in Evoke Pharma in Q3 2018 and held it in 3 quarters.
  • Boothbay Fund Management's Evoke Pharma position peaked at $129K in Q4 2018.
  • 19 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2019.

Based on Boothbay Fund Management's 13F filing for Q2 2019, filed 14 Aug 2019.